论文部分内容阅读
淋巴毒素(Lymphotoxin,LT)是由活化的淋巴细胞分泌的一种糖蛋白。近几年来的研究结果证明:LT有抗肿瘤,抗病毒和参与宿主免疫应答等作用。特别是它的抗肿瘤活性,不少发达国家已把LT作为新一代的抗肿瘤药物加以大力开发。由原代淋巴细胞培养物或RPMI1788细胞株分泌的LT含量甚微,从数十升培养物中只能得到微克级数量的LT,给LT的基础研究和临床应用来了困难。重组人LT使从分子水平上研究LT成为可能。目前,在日本、美国等国,重组LT研究已进入临床Ⅱ期实验,并取得可喜
Lymphotoxin (LT) is a glycoprotein secreted by activated lymphocytes. In recent years, the results show that: LT has anti-tumor, anti-virus and participate in the host immune response and so on. In particular, its anti-tumor activity, many developed countries have LT as a new generation of anti-tumor drugs to be vigorously developed. The level of LT secreted by primary lymphocyte cultures or RPMI1788 cell lines is so small that only microgram quantities of LT are obtained from dozens of liters of culture, making basic research and clinical use of LT difficult. Recombinant human LT makes it possible to study LT at a molecular level. At present, in Japan, the United States and other countries, recombinant LT research has entered the phase Ⅱ clinical trials, and made gratifying